Data gathered: January 9
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated January 7, 2025. Powered by Chat GPT.
Novo Nordisk is a leading global healthcare company, headquartered in Denmark, and specialized in diabetes care, hemophilia, growth disorders, hormonal replacement therapy, and obesity treatment. It is internationally recognized for its wide portfolio of pharmaceutical products, with a strong emphasis on research and development. The company's strategic focus on addressing chronic and lifestyle diseases positions it at the forefront of medical advancements and has paved the way to sustained market leadership.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | January 7 Reddit mentions are up by 169% in the last 24h. |
|
Novo Nordisk | December 21 Reddit mentions are up by 3371% in the last 24h. |
|
Novo Nordisk | December 20 Price is down by -20.2% in the last 24h. |
|
Novo Nordisk | December 20 Trending on Reddit. |
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $85.64 |
| Target Price | Sign up |
| Volume | 9,200,000 |
| Market Cap | $379B |
| Year Range | $83.34 - $146.35 |
| Dividend Yield | 1.74% |
| PE Ratio | 28.25 |
| Analyst Rating | 57% buy |
| Industry | Drug Manufacturers |
In the news
 |
First Hawaiian Bank Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)January 9 - ETF Daily News |
|
International Assets Investment Management LLC Cuts Position in Novo Nordisk A/S (NYSE:NVO)January 9 - ETF Daily News |
UBS Upgrades Novo Nordisk A (NVO)January 8 - Fintel |
|
 |
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck DealsJanuary 8 - Biztoc.com |
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli LillyJanuary 8 - Yahoo Entertainment |
|
 |
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pactJanuary 8 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 34.8B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.710 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 29.4B | 0.730 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$142.27 0% | 45 |
 |
Eli Lilly and CompanyLLY |
$787.22 0% | 57 |
 |
PfizerPFE |
$26.86 0% | 42 |
 |
AstrazenecaAZN |
$66.58 0% | 42 |
 |
AbbVieABBV |
$178.5 0% | 48 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Dec 18, 24 | Sell | $50K - $100K |
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $379B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 28.25.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $85.64.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.74%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.